Back

Risk of qtc interval prolongation among cancer patients treated with tyrosine kinase inhibitors

31 August 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Cardiovascular pharmacotherapy Cardiotoxicity of Drugs ESC Premium Access ESC Congress 2019

6 More presentations in this session

Presentation thumbnail
Research Network in Africa (RNA): quality assessment of antihypertensive generic drugs in 10 African countries
Doctor D. Macquart de Terline (Paris, FR)
Abstract
Presentation thumbnail
Clinical pharmacology of AZD9977, a novel, selective mineralocorticoid receptor (MR) modulator without K+-sparing properties
Doctor A. Whittaker (Gothenburg, SE)
Abstract
Presentation thumbnail
Impact on the prognosis of treatment administrated in the daily clinical practice to patients with myocardial infarction with non-obstructive coronary arteries.
Doctor J. Lopez-Pais (Santiago de Compostela, ES)
Abstract Slides
Presentation thumbnail
Trends in indications and outcome in thrombolytic therapy: a retrospective single center study
Doctor M. Engelen (Leuven, BE)
Abstract Slides
Presentation thumbnail
Cardioprotective anti inflammatory effects of empaglifozin in doxorubicin induced cardiotoxicity: the role of leukotriene B4 and interleukin 1
Doctor N. Maurea (Naples, IT)
Abstract Slides

Access the full session

Session thumbnail
Cardiovascular pharmacotherapy

The Event

Event poster

ESC Congress 2019

31 August - 4 September 2019

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources